Background: Iodine-131 ((131)I) is a well-established method for the treatment of hyperthyroidism. Following such therapy, patients may experience symptoms relating to early or delayed side effects that can be prevented or minimized if necessary measures are taken. We have noticed an unusual side effect of (131)I therapy in the form of a skin eruption (iododerma) and aimed at assessing the frequency and severity of this side effect.

Material And Methods: Retrospective review of 141 patients treated with (131)I between January 1994 to December 2000 (86 F, 55 M; mean age 41.35 +/- 11.02 years) was performed. The dose of (131)I ranged from 250-500 MBq. Post therapy clinical and biochemical evaluation of thyroid function was done at 6 weeks, 3, 6, and 9 months then annually.

Results: Of the 141 treated patients, 3 patients (2.1%) presented with iododerma 4-6 weeks after (131)I therapy administration. Lesions were observed at both ankles & lower legs in all 3 cases. All lesions disappeared within 6 months with no residual effect. No other skin lesions were seen thereafter during the follow-up period.

Conclusion: Iododerma is a rare complication of (131)I therapy that has not been reported before. It appears within 4-6 weeks after therapy and is a self-limiting condition.

Download full-text PDF

Source

Publication Analysis

Top Keywords

131i therapy
12
4-6 weeks
8
131i
6
therapy
6
skin eruptions
4
eruptions treatment
4
treatment iodine-131
4
iodine-131 hyperthyroidism
4
hyperthyroidism rare
4
rare un-reported
4

Similar Publications

Background: In the context of modern oncology, radiogenic elements have emerged as pivotal tools for targeted cancer therapies. Elements like Iodine-131 and Yttrium-90 offer unique radiological properties that allow precise treatment delivery. This article explores their growing importance and potential in reshaping the landscape of cancer therapy.

View Article and Find Full Text PDF

Purpose: None of the antibody-drug conjugates (ADCs) targeting Claudin 18.2 (CLDN18.2) have received approval from regulatory authorities due to their limited clinical benefits.

View Article and Find Full Text PDF

This study aimed to establish and validate prognostic nomogram models for patients who underwent I therapy for thyroid cancer with distant metastases. The cohort was divided into training (70%) and validation (30%) sets for nomogram development. Univariate and multivariate Cox regression analyses were used to identify independent predictors for overall survival (OS) and progression-free survival (PFS).

View Article and Find Full Text PDF

Our aim is to report methodology that has been developed to calibrate and verify PET and SPECT quantitative image accuracy and quality assurance for use with nonstandard radionuclides, especially with longer half-lives, in clinical imaging trials. Procedures have been developed for quantitative PET and SPECT image calibration for use in clinical trials. The protocol uses a 3-step approach: check quantitative accuracy with a previously calibrated radionuclide in a simple geometry, check the novel trial radionuclide in the same geometry, and check the novel radionuclide in a more challenging, complex geometry (the National Electrical Manufacturers Association [NEMA] NU-2 International Electrotechnical Commission [IEC] image-quality phantom).

View Article and Find Full Text PDF

Objectives: To evaluate the characteristics related to oral health and salivary production in patients with Differentiated Thyroid Carcinoma (DTC) after radioiodine therapy (RIT).

Methods: Cross-sectional study, which included patients with DTC after ablative and/or adjuvant RIT. Patients underwent assessment of oral health conditions, subjective assessment of xerostomia and measurement of salivary flow.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!